leflunomide has been researched along with Reperfusion Injury in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is an isoxazole derivative, and a unique immunomodulatory agent." | 5.33 | Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. ( Fadillioglu, E; Karaman, A; Tas, E; Turkmen, E; Yilmaz, Z, 2006) |
| "Leflunomide treatment increased regulatory T cells (Tregs; forkhead box P3+) and IL-10-positive cells but reduced IL-17- and IL-23-expressing cells in both the peripheral blood and kidney cells, indicative of down-regulation of inflammatory responses." | 1.38 | Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells. ( Baban, B; Liu, JY; Mozaffari, MS, 2012) |
| "Leflunomide is an isoxazole derivative, and a unique immunomodulatory agent." | 1.33 | Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. ( Fadillioglu, E; Karaman, A; Tas, E; Turkmen, E; Yilmaz, Z, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yildiz, Y | 1 |
| Kose, H | 1 |
| Cecen, S | 1 |
| Ergin, K | 1 |
| Demir, EM | 1 |
| Serter, M | 1 |
| Bloudícková, S | 1 |
| Rajnoch, J | 1 |
| Lodererová, A | 1 |
| Honsová, E | 1 |
| Viklický, O | 1 |
| Baban, B | 1 |
| Liu, JY | 1 |
| Mozaffari, MS | 1 |
| Karaman, A | 2 |
| Fadillioglu, E | 2 |
| Turkmen, E | 2 |
| Tas, E | 2 |
| Yilmaz, Z | 1 |
| Gursul, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS[NCT03464448] | 30 participants (Actual) | Observational | 2018-04-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for leflunomide and Reperfusion Injury
| Article | Year |
|---|---|
Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catalase; Disease Models, Animal; Dose-Response Re | 2010 |
Leflunomide derivate FK 778 in accelerated renal injury in transgenic rat.
Topics: Alkynes; Animals; Blood Pressure; Disease Models, Animal; Immunosuppressive Agents; Isoxazoles; Kidn | 2010 |
Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Gene Expression Regulation; Inflammatio | 2012 |
Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Female; Hepatocytes; Isoxazoles; Lef | 2006 |
Prevention of renal ischemia/reperfusion-induced injury in rats by leflunomide.
Topics: Animals; Antioxidants; Aspartate Aminotransferases; Blood Urea Nitrogen; Catalase; Creatinine; Femal | 2006 |